LEADING THE WAY IN ANTI-CANCER DRUG DISCOVERY & DEVELOPMENT

Over the past several decades, Taiho has had a successful track record of producing anti-cancer treatments. These successes have brought us to where we are today, with a strong vision to lead the charge in combining conventional and targeted agents. Our unique two-pronged approach of continuously leveraging expertise in anti-metabolite therapies while also combining them with molecular targeted agents, has uncovered a wide range of potentially promising treatments for the future.

The content listed here is representative of Taiho Oncology Inc. sponsored/co-sponsored studies, aligned with latest information available in http://clinicaltrials.gov.
For a listing of Taiho studies globally, please see the following.

Taiho Pharmaceutical Company

Preclinical
Phase 1
Phase 2
Phase 3
Filed

COMPOUND/MOA	COMPOUND/MOA	INDICATION
^1,2FUTIBATINIB Fibroblast growth factor receptor (FGFR) 1-4 inhibitor	Cholangiocarcinoma second line therapy (Pivotal Phase 2)	FILED
TAS0612 Small molecule triple kinase inhibitor of RSK1,2,3,4, AKT1,2,3 and S6K1,2	Solid Tumors	PHASE 1
TAS2940 Covalent pan-ERBB inhibitor with high potency against HER2/EGFR exon20 insertion	Solid Tumors	PHASE 1
TAS3351 4th Generation EGFR-TKI	Non-Small Cell Lung Cancer	PHASE 1

All data is current as of August 2023.

* This material contains information regarding investigational agents that, unless otherwise indicated have not been approved for commercial use by any country's Regulatory Authority. The efficacy and safety for these investigational agents has not been established. There is no guarantee that these compounds will become commercially available or proven safe and effective for any particular therapeutic indication.

¹US: Lytgobi® (futibatinib) was granted accelerated approval for the treatment of adult patients with previously treated, unresectable, locally advanced or metastatic intrahepatic cholangiocarcinoma harboring fibroblast growth factor receptor 2 (FGFR2) gene fusions or other rearrangements.

¹EU: Lytgobi® (futibatinib) has conditional marketing authorisation in the EU as monotherapy for the treatment of adult patients with locally advanced or metastatic cholangiocarcinoma with a fibroblast growth factor receptor 2 (FGFR2) fusion or rearrangement that have progressed after at least one prior line of systemic therapy.

²Registrational study to confirm the safety and efficacy of futibatinib in adult patients with locally advanced or metastatic cholangiocarcinoma with FGFR2 fusions or rearrangements that has progressed after at least one line of prior systemic therapy.